Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Elixinol Wellness ( (AU:EXL) ) has shared an announcement.
Elixinol Wellness Limited has announced the appointment of Gavin Evans as a director, effective December 2, 2025. Evans holds 50,000,000 unlisted options and 7,407,407 fully paid ordinary shares, indicating a significant stake in the company. This appointment may influence the company’s strategic direction and could impact its market positioning, potentially affecting stakeholders’ interests.
The most recent analyst rating on (AU:EXL) stock is a Hold with a A$0.01 price target. To see the full list of analyst forecasts on Elixinol Wellness stock, see the AU:EXL Stock Forecast page.
More about Elixinol Wellness
Elixinol Wellness Limited operates in the wellness industry, focusing on the production and distribution of health and wellness products. The company is known for its offerings in the hemp-derived CBD market, catering to consumers seeking natural health solutions.
YTD Price Performance: -71.05%
Average Trading Volume: 554,520
Technical Sentiment Signal: Sell
Current Market Cap: A$4.55M
Find detailed analytics on EXL stock on TipRanks’ Stock Analysis page.